The arterial disease is less severe in HGPS mice treated with a farnesyltransferase inhibitor (14), an antisense oligonucleotide that alters RNA splicing and reduces progerin expression (11), or by inhibiting N-acetyltransferase 10 (15), endoplasmic reticulum stress (16), MMP13 (17), or ICMT (18). Here, LMNA is linked to arterial disorder.